Related Experiment Video
Updated: Feb 10, 2026

Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
Drug Development for Asthma and COPD: A Regulatory Perspective
Marianne Mann1, Robert J Meyer2
1Dr Mann is an independent clinical/regulatory drug development consultant in Highland, Maryland. mann612@verizon.net rjm7cd@virginia.edu.
Abstract:
This review addresses drug development intended to support United States clearance for asthma and COPD by explaining basic regulatory terms and broadly discussing the regulatory pathways to clearance. Some of the key clinical regulatory challenges that are faced by drugs for asthma and COPD are explained and clarified, both overall and by class of drug, citing relevant examples that emphasize key lessons. Generic drug development of inhaled drugs is also addressed. The purpose of this review is to provide the reader with a greater understanding and appreciation of asthma and COPD drug development from the regulatory perspective.
Related Concept Videos
Cis-regulatory Sequences
Drug Control Governance: Regulatory Bodies and Their Impact
Asthma-I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
COPD: Management Using Bronchodilators and Corticosteroids
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...

